Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a clinical study ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up ...

Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, ...